about
Cardiotoxicity following cyclophosphamidetherapy: a case reportChanges in echocardiographic measures of systolic and diastolic function in children 1 year after hematopoietic SCTGlutathione S-transferase P protects against cyclophosphamide-induced cardiotoxicity in mice.Inhibition of gene expression of organic cation/carnitine transporter and antioxidant enzymes in oxazaphosphorines-induced acute cardiomyopathic rat models.Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantationCardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective studyCase Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor.Guidelines of the Brazilian society of bone Marrow transplantation on hematopoietic stem cell transplantation as a treatment for the autoimmune diseases systemic sclerosis and multiple sclerosis.Chemoprotective potential of Coccinia indica against cyclophosphamide-induced toxicityIncreased sensitivity of glutathione S-transferase P-null mice to cyclophosphamide-induced urinary bladder toxicity.Outcome of hematopoietic stem cell transplant in children with congenital heart disease.Complications of autologous hematopoietic stem cell transplantation for patients with autoimmune diseases.Antineoplastic drug-induced bradyarrhythmias.Metabolic syndrome in patients with hematological diseases.Educational paper: decreasing the burden of cardiovascular disease in childhood cancer survivors: an update for the pediatrician.Cyclophosphamide-associated cardiotoxicity in a child after stem cell transplantation for β-thalassemia major: case report and review of the literature.Cancer chemotherapy and cardiac arrhythmias: a review.Update on cardiotoxicity of anti-cancer treatments.Cardiomyopathy in patients after posttransplant cyclophosphamide-based hematopoietic cell transplantation.Exercise and Aerobic Fitness to Reduce Cancer-Related Cardiovascular Toxicity.Induction of cell death by a novel naphthoquinone containing a modified anthracycline ring system.The clinical features of fatal cyclophosphamide-induced cardiotoxicity in a conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT).Can we find a good biochemical marker of early cardiotoxicity in children treated with haematopoietic stem cell transplantation?Cyclophosphamide-evoked heart failure involves pronounced co-suppression of cytoplasmic thioredoxin reductase activity and non-protein free thiol level.Cladribine inhibits a diltiazem-induced increase in red blood cell purine nucleotide concentrations in a zebrafish model.Acute physiological responses to physiotherapy applications pre and post autologous stem cell transplantation: an experimental study.Very acute cardiac toxicity during BEAC chemotherapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation.B-cell function after unrelated umbilical cord blood transplantation using a minimal-intensity conditioning regimen in patients with X-SCID.Cardiac effects within 3 months of BEAC high-dose therapy in non-Hodgkin's lymphoma patients undergoing autologous stem cell transplantation.Acute and fatal cardiotoxicity following high-dose cyclophosphamide in a patient undergoing autologous stem cell transplantation for systemic sclerosis despite satisfactory cardiopulmonary screening.Pericardial Disease in Cancer Patients.Autologous Hematopoietic Stem Cell Transplantation for Treatment of Systemic Sclerosis
P2860
Q33930737-4E2DC479-DFBD-440D-B8E8-E5EBF3EE2683Q35019395-F9E09038-FE2F-459D-8FE5-1464BD6E336FQ35602805-08EA0CD1-8924-4D31-BC78-FF064CA32F7EQ36014607-44334E38-6348-4DEA-9699-79E70B3D1349Q36176670-0DF601BD-5759-4D49-8F70-1DB4852AB319Q36613992-AB0FDC0B-EB6D-47A5-BDC8-57631BCF9A45Q36757071-D3EECD5B-FAB1-4855-BA07-4D39D35A10EAQ36901406-314B48EE-6A12-4138-B041-9C1A9B8B4F4AQ37222490-5AC786E3-4EF4-40AA-A510-00A48D35CC68Q37416463-38FED07A-6854-4A27-95E8-45CFEA3B180DQ37719670-2E3F5A48-AF1C-44E7-A895-E45533505483Q37995011-52D27147-CCBE-40A7-BD04-32BB77152D19Q38025714-2EF21532-2A4B-44D0-9DD9-27DFEA931E17Q38044776-AFF18305-8A3F-4168-85E8-32D8822A38E2Q38077713-6DD05A3E-41F1-4065-93DE-BEDC4F48BBE3Q38154349-BD53CB8E-609B-4591-A110-884474CCD649Q38313870-8CBDE831-E88F-4C75-97AF-CAD0A2E10ACAQ38686222-71440ABF-F471-4C72-BB50-E6756A46B83AQ38750270-08FA7F12-390A-4157-8DBD-C71236AF0BB1Q38834995-8DD840FA-694B-4FBB-AC18-E1678C1B5623Q39491036-5C5FAE56-8509-4D0B-AF7D-CFBA617734DEQ40713867-82C648A2-A84F-48BB-B480-441477484D40Q41030597-5396EC13-4E22-470A-BA9F-03860D82E475Q43184050-F1981D9C-D94B-4588-AEFF-335CE210221EQ43225680-A60E415F-5DEC-46BF-ABF9-8C063A018F5CQ44219898-9956D927-23B0-4329-B6BA-8626C245CCC9Q46772677-9B7FF35C-57F7-48D4-9EDE-8BDACCCA7915Q46865156-E11A2998-D07A-4F9B-AA51-78AA165C6599Q48466932-1DFC6650-9F02-4B12-A8A1-63608A444299Q50225363-BCD8CF5D-E2F0-4B7A-8BC6-7B42645296F7Q55499983-409CCD20-F040-480B-95D6-100CB51B7460Q58553753-DDC03BCE-023B-4FF0-92F9-8BD358A92BF7
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Cardiac toxicity of high-dose chemotherapy.
@ast
Cardiac toxicity of high-dose chemotherapy.
@en
type
label
Cardiac toxicity of high-dose chemotherapy.
@ast
Cardiac toxicity of high-dose chemotherapy.
@en
prefLabel
Cardiac toxicity of high-dose chemotherapy.
@ast
Cardiac toxicity of high-dose chemotherapy.
@en
P2093
P2860
P356
P1476
Cardiac toxicity of high-dose chemotherapy.
@en
P2093
Benvenuto GM
Raimondi R
Ruffini PA
P2860
P2888
P304
P356
10.1038/SJ.BMT.1704763
P407
P577
2005-02-01T00:00:00Z